300 filings
8-K
FOLD
Amicus Therapeutics Inc
28 Feb 24
Amicus Therapeutics Announces Full-Year 2023 Financial Results and Corporate Updates
7:02am
8-K
FOLD
Amicus Therapeutics Inc
8 Jan 24
Amicus Therapeutics Reports Preliminary 2023 Revenue and Provides 2024 Strategic Outlook
7:01am
8-K
FOLD
Amicus Therapeutics Inc
5 Dec 23
Amicus Therapeutics Congratulates Executive Chairman John F. Crowley on Appointment as Next President and CEO of BIO
6:03am
8-K
FOLD
Amicus Therapeutics Inc
8 Nov 23
Amicus Therapeutics Announces Third Quarter 2023 Financial Results and Corporate Updates
7:00am
8-K
FOLD
Amicus Therapeutics Inc
5 Oct 23
Termination of a Material Definitive Agreement
5:00pm
8-K
2tr2ho1
2 Oct 23
Entry into a Material Definitive Agreement
8:48am
8-K
8b8awufj
28 Sep 23
Amicus Therapeutics Announces FDA Approval and Launch of New Treatment for Pompe Disease
12:00pm
8-K
q1xh ab07jii0
27 Sep 23
AT THE FOREFRONT OF THERAPIES FOR RARE DISEASES Corporate Overview September 2023
7:00am
8-K
p3693n bfvqeh
21 Aug 23
Amicus Therapeutics Appoints Simon Harford as Chief Financial Officer
7:01am
8-K
ghhlp4s 3ggj8srn
15 Aug 23
Amicus Therapeutics Announces Approval and Launch of New Pompe Disease Therapy in the United Kingdom
7:00am
8-K
waw643na p3vhmv3p
8 Aug 23
Amicus Therapeutics Announces Second Quarter 2023 Financial Results and Corporate Updates
7:00am
8-K
deh1ee4x7v8f517m7yb
13 Jul 23
Departure of Directors or Certain Officers
5:00pm
8-K
3jwcksql5c tfpcga
27 Jun 23
Amicus Therapeutics Announces Approval and Launch of New Pompe Disease Therapy in the European Union
7:01am
8-K
yovv3ys5mvmcm
13 Jun 23
Amendments to Articles of Incorporation or Bylaws
4:30pm
8-K
r4wias pi
12 May 23
Entry into a Material Definitive Agreement
5:08pm
8-K
1xqz1unv59vjml
10 May 23
Amicus Therapeutics Announces First Quarter 2023 Financial Results and Corporate Updates
7:01am
8-K
zkuj7n9 urh1
26 Apr 23
Amicus Therapeutics Receives Positive CHMP Opinion for Opfolda® (miglustat) for Late-Onset Pompe Disease
2:04pm
8-K
67txu6k
24 Apr 23
Entry into a Material Definitive Agreement
8:44am
8-K
qrlyss 2mu22gj
27 Mar 23
Approved as a Long-Term Enzyme Replacement Therapy in Combination with Miglustat for All Adults Living with Late-Onset Pompe Disease
7:00am
8-K
7vzw5gxgn
1 Mar 23
Amicus Therapeutics Announces Full-Year 2022 Financial Results and Corporate Updates
7:01am